Navigation Links
Anavex advances drug candidate for treatment of Alzheimer's disease
Date:11/28/2007

lt of the destruction of nerve cells in the brain. Dementia affects an estimated 37 million people worldwide and approximately 50% of these cases are caused by Alzheimer's disease. In March 2007, the Alzheimer's Association reported that 5.1 million people in the United States (4.9 million of whom are aged 65 and older) are living with Alzheimer's disease. This represents an increase of at least 10% from the previous prevalence estimate of 4.5 million. By 2015, there could be as many as 16.8 million people with Alzheimer's disease in the major seven pharmaceutical markets unless novel drug treatment therapies are discovered.

Medications currently available to treat Alzheimer's disease include acetylcholinesterase inhibitors and N-methyl-D aspartate receptor antagonists. Both types of medications only treat symptoms of the disease - they do not stop the onset and progression of Alzheimer's disease.

In conclusion, there are very real and unmet medical requirements for drug therapies to treat Alzheimer's disease. The impressive market size leaves no doubt for the business opportunity presented by treatments for Alzheimer's disease.

Drugs able to act on the underlying disease pathology and modify disease onset and progression, demonstrating neuroprotective, anti-amnesic and preventive properties combined with excellent safety and low toxicity, have the potential for blockbuster sales.

About Sigma Receptors

Sigma receptors are a unique family of proteins, present mainly in the Central Nervous System (CNS) but also in various peripheral tissues. The receptors are classified in two subtypes: the sigma-1 and sigma-2. These subtypes are distinguishable pharmacologically, functionally and by molecular size. Sigma-1 receptors have been cloned and shown to be distinct from any known receptor class.

In the CNS, they are involved in the modulation of neurotransmitter receptor function, neurotransmitter release and response, as well as mem
'/>"/>

SOURCE Anavex Life Sciences Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
2. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
3. Verenium Advances Its Development Work With Cargill on a New Food-Related Product
4. EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference
5. Response Genetics CEO to Discuss Advances in Optimizing Therapy through Pharmacogenomics as Part of a Series of Presentations at AACR-NCI-EORTC International Conference
6. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
7. KineMed to Collaborate With Merck KgaA to Validate New Applications for Drug Development Candidates
8. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
9. BioSpace Draws Over 600 Candidates to San Diego Life Science Career Fair
10. Astex Drug Candidates to be Featured at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
11. First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Freeslate, Inc ., ... announced that Lupin Limited, one of India’s top five ... Protégé PharmD System for high throughput solid form ... focused on a wide range of quality, affordable generic ...
(Date:1/14/2014)... Diego, CA (PRWEB) January 14, 2014 ... on the products of cells grown under simulated embryonic ... international license agreement with Suneva Medical, Inc. for physician-dispensed ... (CCM). , This agreement is an amendment ...
(Date:1/14/2014)... Md. , Jan. 14, 2014  Organovo announced today ... the National Institutes of Health (NIH) to help scientists ... treatments to patients on a faster timeline. Organovo is ... (NCATS) and the National Eye Institute (NEI) to develop ...
(Date:1/14/2014)... , Jan. 14, 2014   Kinaxis ®, provider of ... and sales and operations planning ( S&OP ) service, is ... Summit , which will be held at the Hilton San ... join Kinaxis customer Elisabeth Kaszas , Director of Supply ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... , REYKJAVIK, Iceland, June 26 ... received notice from the the Nasdaq,Hearing and Listing Review Council ... to the Nasdaq Global Market effective from the,opening of trading ... under the symbol DCGN. , The ...
... TRIANGLE PARK, N.C., June 26 Syngenta Biotechnology, Inc. ... agreement with Evogene, Ltd., focusing on identifying plant genes ... will receive exclusive licensing rights to candidate genes discovered ... Soybean nematode is a soil parasite which attacks the ...
... ... Complex Localization Needs , ... China (PRWEB) June 26, 2009 -- CSOFT International Ltd., a leading provider of ... announced the upcoming launch of L10NPRO 3.0 at its 6th Annual Worldwide Operations Summit in ...
Cached Biology Technology:deCODE Reinstated to Nasdaq Global Market 2deCODE Reinstated to Nasdaq Global Market 3Syngenta and Evogene to Collaborate on Soybean Nematode Resistance 2CSOFT Announces Introduction of L10NPRO 3.0 at 6th Annual Worldwide Summit in Beijing 2CSOFT Announces Introduction of L10NPRO 3.0 at 6th Annual Worldwide Summit in Beijing 3CSOFT Announces Introduction of L10NPRO 3.0 at 6th Annual Worldwide Summit in Beijing 4CSOFT Announces Introduction of L10NPRO 3.0 at 6th Annual Worldwide Summit in Beijing 5
(Date:4/18/2014)... to the story of how barnyard chickens came to be, ... journal Proceedings of the National Academy of Sciences . ... 200-2300 years ago in Europe, researchers report that just a ... different from the chickens we know today. , The results ... domestic chickens -- such as their yellowish skin -- only ...
(Date:4/17/2014)... under clinical trials to treat tuberculosis could be the ... against various bacteria, fungal infections and parasites, yet evade ... chemists and collaborators. , Led by U. of I. ... ways the drug SQ109 attacks the tuberculosis bacterium, how ... from yeast to malaria and how targeting multiple ...
(Date:4/17/2014)... consumption advisories for expecting mothers are ineffective in ... organic pollutants (POPs). , The study, performed ... Toronto Scarborough PhD student Matt Binnington and Professor ... environmental contamination, a mother,s compliance with advisories, and ... exposure in her children. , Their model estimates ...
Breaking Biology News(10 mins):Ancient DNA offers clues to how barnyard chickens came to be 2Multitarget TB drug could treat other diseases, evade resistance 2Fish consumption advisories fail to cover all types of contaminants 2
... must act now if it wants to reach its Minnesota ... by 15 percent by 2015, according to a team of ... research team, which will release the new study Tuesday, July ... possible to reduce emissions by 30 percent by 2025 and ...
... completing one of the longest running experiments ever done ... University of Minnesota and the Freshwater Institute, contend that ... other jurisdictions around the world are investing millions of ... increase the problem of cultural eutrophication. The dramatic ...
... IL, Children,s Memorial Hospital of Chicago announced ... Pharmaceutical Inc. to support its Adult Phenylketonuria (PKU) Outreach ... to conduct outreach to PKU patients who are no ... to return for further education about recent developments in ...
Cached Biology News:Action needed now for Minnesota to reach goals in reducing greenhouse gas emissions by 2015 2Action needed now for Minnesota to reach goals in reducing greenhouse gas emissions by 2015 3Researchers find key to saving the world's lakes 2Children's Memorial Hospital of Chicago receives a grant from BioMarin to support adult PKU outreach 2
Abgene's ALTO-8 is the first automated decapper/capper for Abgene Twist-Lock tubes....
... refrigerated multifunction centrifuges are equally capable of high ... sound level with a large range of rotors ... exchange system without tools ensures that the required ... Instant rotor exchange (5 sec.) with ...
versican (H-56)...
... Shimadzu Biotech presents PsiPort Mass ... data review and data acquisition system ... purification for the life science and ... been designed specifically to simplify high ...
Biology Products: